cnbc.com / .cnbc-com-health-care / Page 2

Whoop is introducing on-demand clinician access and AI-powered health guidance, largely included in the price of membership.

New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.

Shares of Planet Fitness plunged Thursday after the fitness company slashed its guidance and canceled planned price hikes.

Healthcare startups made up nearly a third of April's investments by family offices.

Ultragenyx's Rare Bootcamp gives families a roadmap to help drive research and develop new treatments for rare diseases.

Novo Nordisk CEO Mike Doustdar says the Ozempic and Wegovy maker is looking for deals more than ever before.

Supplement patch company Barrière is launching the first-ever lactose intolerance patch in 1,700 Walmart stores, the company told CNBC exclusively.

All of the health-care giant's business segments, including its insurer Aetna, its retail pharmacy and health services unit, surpassed expectations.

The studies were "withdrawn because the authors drew broad conclusions that were not supported by the underlying data," the spokesperson told CNBC.

U.S. Food and Drug Administration Commissioner Marty Makary, under pressure, defends himself in an interview with CNBC's David Faber.